All US holdings of this investor are reported in this report. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as
of the end of the calendar quarter for which the report is filed, and the total market value. The market value
column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in
accounts.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
David S. Wetherell
Manager
Boston, Massachusetts
5/11/2017
The filing of this report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g), or 16(a) under the Securities Exchange Act of 1934, as amended, and the rules thereunder, or for any other purpose, that the Reporting Manager or any other person (including Other Managers or Other Included Managers named herein) is the beneficial owner of any securities. Biomark Capital Management Co. LLC, a Delaware limited liability company (the "Management Company"), is an institutional investment manager which, for the purposes of Section 13(f) of the Securities Exchange Act of 1934 and the rules promulgated thereunder ("Section 13(f)"), exercises investment discretion with respect to certain securities positions held directly and indirectly by Biomark Capital Fund IV LP, a Delaware limited partnership (the "Fund"). David S. Wetherell, an individual ("Wetherell") and Biomark Capital Fund IV GP LLC, a Delaware limited liability company (the "General Partner"), may each be deemed to exercise investment discretion over the securities reported on this Form 13F for purposes of Section 13(f). Certain of the security positions reported by the Management Company are also being reported by Wetherell and the General Partner. Also, 301,861 shares of common stock of Juno Therapeutics, Inc. reported by the Management Company are held by a majority owned portfolio company of the Fund. Each of the Management Company, the General Partner and Wetherell disclaims beneficial ownership of the shares reported on this Form 13F by the Management Company except to the extent of any pecuniary interest therein.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.